Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View

Core Viewpoint - Guardant Health, Inc. is recognized as a promising growth stock with a Moderate Buy consensus from analysts, indicating strong potential for price appreciation in the near term [1][4]. Financial Performance - For Q4 2025, Guardant Health reported revenue of $281.3 million, reflecting a 39% year-over-year increase, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million [2]. - The company anticipates total revenue growth of 27% to 30% for the year 2026 [2]. Strategic Developments - At recent healthcare conferences, Guardant emphasized its partnership with Quest Diagnostics as a significant commercial driver for its Shield product, noting that the potential benefits from this partnership were not included in the 2026 revenue guidance [3]. - Management highlighted that 90% of Shield users had not been screened in the previous five years, suggesting a substantial opportunity for market expansion [3]. - Additional catalysts for growth include potential FDA-related advancements for ESR1 monitoring in Guardant360, although the Reveal Ultra product was excluded from 2026 guidance due to uncertain reimbursement [3]. Analyst Ratings - Piper Sandler analyst David Westenberg maintained a Buy rating on Guardant Health, raising the price target from $120 to $130 following the quarterly release [4].